{"id":"NCT02721966","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement","officialTitle":"MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-03","primaryCompletion":"2019-06-26","completion":"2019-06-26","firstPosted":"2016-03-29","resultsPosted":"2020-08-24","lastUpdate":"2020-10-01"},"enrollment":503,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Axial Psoratic Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["AIN457"]},{"type":"DRUG","name":"Secukinumab and Placebo","otherNames":[]}],"arms":[{"label":"AIN457 150mg","type":"EXPERIMENTAL"},{"label":"AIN457 300mg","type":"EXPERIMENTAL"},{"label":"AIN457 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).","primaryOutcome":{"measure":"Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12","timeFrame":"at week 12","effectByArm":[{"arm":"AIN457 150mg","deltaMin":66.3,"sd":null},{"arm":"AIN457 300mg","deltaMin":62.9,"sd":null},{"arm":"Placebo AIN457","deltaMin":31.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<.0001"},{"comp":"OG001 vs OG002","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":94,"countries":["Belgium","Bulgaria","Czechia","Estonia","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Poland","Romania","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["37094184","33334727"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":248},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Pharyngitis","Bronchitis"]}}